Keywords: Alnylam, RNAi milestone, Influenza vaccine, Production methods, GlaxoSmithKline, GlobalData

Silencing investor concerns? Alnylam achieves RNAi milestone

Article | 02 August 2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone payment from UK pharma giant GlaxoSmithKline (LSE: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

GlaxoSmithKline

Alnylam Pharmaceuticals

Go to company listing